WO2017216727A1 - Substituted pyridines as inhibitors of dnmt1 - Google Patents

Substituted pyridines as inhibitors of dnmt1 Download PDF

Info

Publication number
WO2017216727A1
WO2017216727A1 PCT/IB2017/053511 IB2017053511W WO2017216727A1 WO 2017216727 A1 WO2017216727 A1 WO 2017216727A1 IB 2017053511 W IB2017053511 W IB 2017053511W WO 2017216727 A1 WO2017216727 A1 WO 2017216727A1
Authority
WO
WIPO (PCT)
Prior art keywords
dicyano
thio
phenylacetamide
amino
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2017/053511
Other languages
English (en)
French (fr)
Inventor
Nicholas David ADAMS
Andrew B. Benowitz
Maria Lourdes RUEDA BENEDE
Karen Anderson Evans
David T. Fosbenner
Bryan Wayne KING
Mei Li
Juan Ignacio Luengo
William Henry Miller
Alexander Joseph Reif
Stuart Paul Romeril
Stanley J. Schmidt
Roger J. Butlin
Kristen M. GOLDBERG
Allan M. Jordan
Christopher S. KERSHAW
Ali Raoof
Bohdan WASZKOWYCS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
Cancer Research Technology Ltd
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201780036908.XA priority Critical patent/CN109563043B/zh
Priority to US16/309,121 priority patent/US10975056B2/en
Priority to CA3026211A priority patent/CA3026211A1/en
Priority to BR112018075992-9A priority patent/BR112018075992B1/pt
Priority to AU2017283790A priority patent/AU2017283790B2/en
Priority to ES17733902T priority patent/ES2993451T3/es
Priority to MX2018015483A priority patent/MX391600B/es
Priority to CR20180580A priority patent/CR20180580A/es
Priority to KR1020197000766A priority patent/KR20190017030A/ko
Priority to EA201990023A priority patent/EA038355B1/ru
Priority to PH1/2018/502633A priority patent/PH12018502633B1/en
Priority to JP2019517187A priority patent/JP7051829B2/ja
Application filed by Cancer Research Technology Ltd, GlaxoSmithKline Intellectual Property Development Ltd filed Critical Cancer Research Technology Ltd
Priority to SG11201809559UA priority patent/SG11201809559UA/en
Priority to EP17733902.5A priority patent/EP3468953B1/en
Publication of WO2017216727A1 publication Critical patent/WO2017216727A1/en
Priority to IL263163A priority patent/IL263163B/en
Priority to JOP/2018/0120A priority patent/JOP20180120A1/ar
Anticipated expiration legal-status Critical
Priority to CONC2018/0013717A priority patent/CO2018013717A2/es
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to substituted pyridine derivatives that are selective inhibitors of the activity of DNA methyltransferase1 (DNMT1).
  • DNMT1 DNA methyltransferase1
  • the present invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anaemia, and beta thalassemia, and other diseases associated with DNMT1 inhibition.
  • DNA methyltransferase family of proteins which is comprised of four family members. Three of the family members, DNMT1, DNMT3A and DNMT3B, contain DNA methyltransferase activity. These three members are responsible for establishing the de novo DNA methylation pattern, while DNMT1 is primarily responsible for maintaining the methylation pattern in daughter strands following DNA replication.
  • DNA methylation patterns become aberrant resulting in global hypomethylation and localized hypermethylation within promoter regions. This can result in downstream silencing of tumor suppressor genes (Ting et al. Genes Dev.2006; 20:3215-3231). Additionally, silencing of DNMT1 results in DNA demethylation and reexpression of tumor suppressor genes resulting in tumor growth inhibition (Zhou et al. Oncol. Lett.2014; 5: 2130– 2134).
  • DNA methylation inhibitors (termed DNA hypomethylating agents) are clinically validated anti-cancer therapies utilized for the treatment of MDS, AML and CMML. While these agents are available, there is still significant opportunity for improvement regarding toxicity, utility in solid tumors and oral bioavailability.
  • a novel DNMT inhibitor would be of interest for the treatment of cancer and/or any disease or condition mediated by DNA methylation.
  • DNMT1 is specifically targeting DNMT1 to prevent propagation of abnormal methylation patterns (such as those that occur in cancer) to daughter strands during replication.
  • US 2008/0132525 and WO 2006/078752 describe inhibitors of DNA methyltransferase.
  • CA 2030875 describes methods and probes for detecting nucleoside transporter and method for producing the probes.
  • Hemoglobin disorders such as sickle cell anemia and beta-thalassaemia, represent the most common heritable blood diseases in the world.
  • Sickle cell anemia and beta-thalassemia are characterized by disorders of hemoglobin, which is the oxygen carrying protein complex in red blood cells.
  • hemoglobin is normally composed of two pairs of proteins plus four molecules of heme.
  • adult hemoglobin which predominantly consists of two alpha-globin proteins paired with two beta-globin proteins plus four molecules of heme.
  • fetal hemoglobin which is composed of two alpha-globin proteins paired with two gamma-globin proteins plus four molecules of heme.
  • G-gamma and A-gamma there are two forms of gamma-globin, termed G-gamma and A-gamma, that are encoded by two different genes (HBG1 and HBG2) but that are functionally equivalent to a large degree; fetal hemoglobin refers to any combination of a pair of G-gamma and/or A-gamma plus a pair of alpha- globin proteins plus four molecules of heme.
  • beta-globin In sickle cell anemia, the gene encoding for beta-globin contains a mutation which results in an abnormal hemoglobin structure and causes red blood cells to adopt a characteristic sickle shape under certain conditions. This sickle shape leads to reduced red cell plasticity, longer capillary transit times, and frequent vaso-occlusive processes that can damage tissues and result in patient morbidity.
  • beta-thalassemia is characterized by inadequate beta-globin production to combine with normally produced alpha-globin. The resulting accumulation of alpha globin is toxic to red blood cell precursors, and results in ineffective erythropoiesis and extensive red blood cell hemolysis. There is currently no approved pharmacologic treatment to cure sickle cell anemia or beta-thalassemia.
  • promoters of the HBG1 and HBG2 loci are highly methylated, resulting in greatly diminished expression of gamma-globin proteins (3).
  • DNA methyltransferases DNMT1, DNMT3A, and DNMT3B are each expressed in erythroid progenitors, the relatively greater expression of DNMT1, particularly in the final stages of erythroid differentiation suggests that it plays a dominant role in globin gene regulation (2).
  • 5-azacytidine and 5-aza-2’-deoxycytidine (decitabine) are pan-DNMT inhibitors that are known inducers of fetal hemoglobin in erythroid progenitor cells.
  • the invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar):
  • Y ar , X 1ar , X 2ar , R 1ar , R 2ar , R 3ar , R 4ar and R 5ar are as defined below; or a pharmaceutically acceptable salt or prodrug thereof.
  • the present invention also relates to the discovery that the compounds of Formula (I) are active as inhibitors of DNMT1, and selective against DNMT3A and DNMT3B.
  • This invention also relates to a method of treating cancer, which comprises administering to a subject in need thereof an effective amount of a DNMT1 inhibiting compound of Formula (I); or a pharmaceutically acceptable salt thereof.
  • This invention also relates to a method of treating pre-cancerous syndromes, which comprises administering to a subject in need thereof an effective amount of a DNMT1 inhibiting compound of Formula (I); or a pharmaceutically acceptable salt thereof.
  • This invention also relates to a method of treating beta hemoglobinopathies, which comprises administering to a subject in need thereof an effective amount of a DNMT1 inhibiting compound of Formula (I); or a pharmaceutically acceptable salt thereof.
  • This invention also relates to a method of treating sickle cell disease, which comprises administering to a subject in need thereof an effective amount of a DNMT1 inhibiting compound of Formula (I); or a pharmaceutically acceptable salt thereof.
  • This invention also relates to a method of treating sickle cell anemia, which comprises administering to a subject in need thereof an effective amount of a DNMT1 inhibiting compound of Formula (I); or a pharmaceutically acceptable salt thereof.
  • This invention also relates to a method of treating beta thalassemia, which comprises administering to a subject in need thereof an effective amount of a DNMT1 inhibiting compound of Formula (I); or a pharmaceutically acceptable salt thereof.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in therapy.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of cancer.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of pre-cancerous syndromes.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of beta hemoglobinopathies.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of sickle cell disease.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of sickle cell anemia.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of beta thalassemia.
  • the invention also relates to the use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer.
  • the invention also relates to the use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of pre-cancerous syndromes.
  • the invention also relates to the use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of beta hemoglobinopathies.
  • the invention also relates to the use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of sickle cell disease.
  • the invention also relates to the use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of sickle cell anemia.
  • the invention also relates to the use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of beta thalassemia.
  • pharmaceutical compositions that comprise a pharmaceutical carrier and a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention also relates to a pharmaceutical composition as defined above for use in therapy. Also included in the present invention are methods of co-administering the presently invented DNMT1 inhibiting compounds with a further anti-neoplastic agent or agents.
  • the invention also relates to a combination for use in therapy which comprises a therapeutically effective amount of (i) a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and (ii) at least one anti-neoplastic agent.
  • the invention also relates to a combination for use in therapy which comprises a therapeutically effective amount of (i) a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and (ii) at least one further fetal hemoglobin inducing agent.
  • the invention also relates to a combination for use in therapy which comprises a therapeutically effective amount of (i) a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and (ii) at least one further agent that lessens the severity of beta hemoglobinopathies.
  • the invention also relates to a combination for use in therapy which comprises a therapeutically effective amount of (i) a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and (ii) at least one further agent that lessens the severity of sickle cell anemia.
  • the invention also relates to a combination for use in therapy which comprises a therapeutically effective amount of (i) a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and (ii) at least one further agent that lessens the severity of sickle cell disease.
  • the invention also relates to a combination for use in therapy which comprises a therapeutically effective amount of (i) a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and (ii) at least one further agent that lessens the severity of beta thalassemia.
  • EPCs Erythroid progenitor cells
  • vehicle gray bars
  • Compound A black bars
  • genomic DNA was extracted and bisulfite sequenced for nine loci in the promoter regions of HBG1 and HBG2 that were previously described to be sites of DNMT1 cytosine methylation. Sites of methylation are labeled as positions relative to respective start sites
  • Figure– 2A depicts the effect of Compound A on fetal hemoglobin in the transgenic mouse model.
  • SCD sickle cell disease
  • Figure– 2B depicts the effect of Compound A on fetal hemoglobin in the transgenic mouse model.
  • Compound A administered orally to SCD transgenic mice at 10 or 50 mg/kg, BID daily caused dose dependent increases in %F- reticulocytes and %F-RBCs, measured by flow cytometry.
  • BID daily caused dose dependent increases in %F- reticulocytes and %F-RBCs, measured by flow cytometry.
  • This invention relates to compounds of Formula (lar) and to the use of compounds of Formula (lar) in the methods of the invention:
  • X 1 ar and X 2ar are independently selected from: hydrogen,
  • heterocycloalkyi substituted from 1 to 4 times by
  • Y ar is selected from: S, NH, NR Z , O, S(O) and S(O)2;
  • R 1 ar is selected from: amino,
  • R is selected from: hydrogen,
  • R 3ar is selected from: hydrogen
  • heteroaryl substituted from 1 to 4 times by R d is selected from: hydrogen,
  • R 5ar is selected from: amino
  • each R a is independently selected from
  • R d heterocycloalkyi substituted from 1 to 4 times by R d ; and R c are independently selected from:
  • R and R are taken together with the nitrogen to which they are attached, and optionally from 1 to 3 additional heteroatoms, to form a heterocycloalkyi, which is optionally substituted with from 1 to 5 substituents independently selected from:
  • cycloalkyl substituted from 1 to 4 times by R d , heterocycloalkyi, and
  • each R is independently selected from: fluoro,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN, cycloalkyi,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x1 and R x2 are each independently selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R and R are each independently selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x1 and R x2 are each independently selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x1 and R x2 are each independently selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH,
  • each R e is independently selected from:
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH,
  • R xx is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OR xy , -COOH, -CN, -OC1 -Salkyl, -OCi -Salkyl substituted from 1 to 6 times by fluoro and where R xy and R xz are independently
  • Ci-5alkyl substituted with from 1 to 4 substituents independently selected from: fluoro, oxo, -OH,
  • R x1 and R x2 are each independently selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 Substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -C -C
  • X 1 and X 2 are independently selected from: hydrogen,
  • Y is selected from: S, NH, NR Z , O, S(O) and S(O)2;
  • R is selected from: amino
  • R 2 is selected from: hydrogen, C 1 -6 alkyl,
  • R 3 is selected from: hydrogen,
  • heteroaryl substituted from 1 to 4 times by R d is selected from: hydrogen,
  • each R a is independently selected from
  • heterocycloalkyi substituted from 1 to 4 times by R d and R c are independently selected from:
  • heterocycloalkyi substituted from 1 to 4 times by R , or and R c are taken together with the nitrogen to which they are attached, and optionally from 1 to 3 additional heteroatoms, to form a heterocycloalkyi, which is optionally substituted with from 1 to 5 substituents independently selected from:
  • heterocycloalkyi substituted from 1 to 4 times by R d , C 1 -4 alkoxy,
  • Ci-4alkoxy substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH,
  • each R is independently selected from: fluoro,
  • R x is selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro oxo -OH -COOH -NH2 and— CN
  • R x is selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN, hydroxy,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x1 and R x2 are each independently selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and -CN,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x1 and R x2 are each independently selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and -CN,
  • each R e is independently selected from:
  • -OC 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and— CN,
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocyloalkyi, C 1 -6 alkyl, and C 1 -6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH 2 , and–-CN, h
  • e ach R is independently heteroaryl optionally substituted from 1 to 5 x
  • R is independently selected from aryl, h eteroaryl, cycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, - NH 2 , and–-CN, and z
  • R is selected from
  • R is selected from
  • At least one of R , R and R is hydrogen
  • R , R and R are not all hydrogen
  • X and X are not both hydrogen; or a pharmaceutically acceptable salt or prodrug thereof.
  • X and X are not both hydrogen; or a pharmaceutically acceptable salt or prodrug thereof.
  • Included in the compounds of the invention and used in the methods of the invention are compounds of Formula (II):
  • X and X are independently selected from: hydrogen,
  • Y is selected from: S, NH, NR , S(O) and S(O)2; 2 1
  • R is selected from: amino
  • R 22 is selected from: hydrogen,
  • R is selected from: hydrogen,
  • R is selected from: hydrogen,
  • R 25 is selected from: amino,
  • e ach R is independently selected from
  • R and R are independently selected from:
  • R and R are taken together with the nitrogen to which they are attached, and optionally from 1 to 3 additional heteroatoms, to form a heterocycloalkyl, which is optionally substituted with from 1 to 5 substituents independently selected from:
  • e ach R is independently selected from: fluoro
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH 2 , and–-CN, cycloalkyl,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH 2 , and–-CN, heterocycloalkyl,
  • R is selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyl, C1-6alkyl, and C1-6alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH 2 , and–-CN, aryl,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH 2 , and–-CN, C 1-4 alkoxy,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH 2 , and–-CN, -C(O)H,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH 2 , and–-CN, -S(O)H,
  • R is selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyl, C1-6alkyl, and C1-6alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH 2 , and–-CN, -S(O) 2 H,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH 2 , and–-CN, -S(O) 2 NH 2 ,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH 2 , and–-CN, x 1 x2
  • R and R are each independently selected from a ryl, heteroaryl, cycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, - NH 2 , and–-CN,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH 2 , and–-CN, -NHC(O)H,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH 2 , and–-CN, -C(O)NH 2 ,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH 2 , and–-CN, x 1 x2
  • R and R are each independently selected from a ryl, heteroaryl, cycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, - NH 2 , and–-CN,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH 2 , and–-CN, oxo,
  • R is selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH 2 , and–-CN, x 1 x2
  • R and R are each independently selected from a ryl, heteroaryl, cycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, - NH 2 , and–-CN,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH 2 , and–-CN, x 1 x2
  • R and R are each independently selected from a ryl, heteroaryl, cycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, - NH 2 , and–-CN,
  • e ach R is independently selected from:
  • - OC 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, - COOH, -NH 2 , and–-CN, mercapto,
  • R is selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, - COOH, -NH 2 , and–-CN,
  • R is selected from aryl, heteroaryl, c ycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, - COOH, -NH 2 , and–-CN,
  • R is selected from aryl, heteroaryl, c ycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, - COOH, -NH 2 , and–-CN,
  • R is selected from aryl, heteroaryl, c ycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C1-6alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, x y
  • R and R are each independently selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 Substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH 2 , and–-CN, guanidino,
  • R is selected from aryl, heteroaryl, c ycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, - COOH, -NH 2 , and–-CN,
  • R is selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyl, C1-6alkyl, and C1-6alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, - COOH, -NH 2 , and–-CN,
  • R and R are each independently selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 Substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH 2 , and–-CN, aryl,
  • R is selected from aryl, heteroaryl, c ycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, - COOH, -NH 2 , and–-CN,
  • R is selected from aryl, heteroaryl, c ycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, - COOH, -NH 2 , and–-CN,
  • R is selected from aryl, heteroaryl, c ycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, - COOH, -NH 2 , and–-CN,
  • R is selected from aryl, heteroaryl, c ycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, - COOH, -NH 2 , and–-CN,
  • R is selected from aryl, heteroaryl, c ycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, - COOH, -NH 2 , and–-CN,
  • R is selected from aryl, heteroaryl, c ycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, - COOH, -NH 2 , and–-CN,
  • R is selected from aryl, heteroaryl, c ycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, - COOH, -NH 2 , and–-CN,
  • R and R are each independently selected from aryl, heteroaryl, cycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 Substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH 2 , and–-CN, - NHS(O) 2 H,
  • R is selected from aryl, heteroaryl, c ycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, - COOH, -NH 2 , and–-CN, xp
  • R is selected from heteroaryl, c ycloalkyl, heterocyloalkyl, and C 1-6 alkyl substituted with from 1 to 4 substituents independently selected from: -COOH, -NH 2 , and –-CN,
  • R and R are each independently selected from heteroaryl, cycloalkyl, heterocyloalkyl, a nd C 1-6 alkyl substituted with from 1 to 6 Substituents independently selected from: - COOH, -NH 2 , and–-CN, nitro, and
  • each R is independently C 1-6 alkyl optionally substituted from 1 to 6 times e
  • e ach R is independently aryl optionally substituted from 1 to 5 times by x
  • R is independently selected from aryl, heteroaryl, c ycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH 2 , and–-CN, h
  • e ach R is independently heteroaryl optionally substituted from 1 to 5 x
  • R is independently selected from aryl, h eteroaryl, cycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents Independently selected from: fluoro, oxo, -OH, -COOH, - NH 2 , and–-CN, and z
  • R is selected from
  • R is selected from
  • At least one of R , R and R is hydro
  • R , R and R are not all hydrogen
  • X and X are not both hydrogen; or a pharmaceutically acceptable salt or prodrug thereof.
  • X and X are compounds of Formula (III):
  • X and X are independently selected from: hydrogen,
  • Y is selected from: S, NH, NR and S(O);
  • R is selected from: C 1-6 alkyl
  • R is selected from: hydrogen,
  • R 33 is selected from: hydrogen,
  • R is selected from: hydrogen,
  • R is selected from: amino
  • d 1 a ryl substituted from 1 to 4 times by R , - OC 1-6 alkyl,
  • e ach R is independently selected from
  • R and R are independently selected from:
  • R and R are taken together with the nitrogen to which they are attached, and optionally from 1 to 3 additional heteroatoms, to form a heterocycloalkyl, which is optionally substituted with from 1 to 5 substituents independently selected from:
  • d 1 a ryl substituted from 1 to 4 times by R , cycloalkyl,
  • e ach R is independently selected from: fluoro
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted from 1 to 6 times by fluoro,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted from 1 to 6 times by fluoro,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted from 1 to 6 times by fluoro,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted from 1 to 6 times by fluoro,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted from 1 to 6 times by fluoro,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted from 1 to 6 times by fluoro,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted from 1 to 6 times by fluoro,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted from 1 to 6 times by fluoro,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted from 1 to 6 times by fluoro,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted from 1 to 6 times by fluoro,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted from 1 to 6 times by fluoro,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted from 1 to 6 times by fluoro,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted from 1 to 6 times by fluoro,
  • R is selected from aryl, heteroaryl, cycloalkyl, h eterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted from 1 to 6 times by fluoro; e 1
  • e ach R is independently selected from:
  • - OC 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, - COOH, -NH 2 , and–-CN, mercapto,
  • R is selected from aryl, heteroaryl, c ycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted from 1 to 6 times by fluoro, -S(O)H,
  • R is selected from aryl, heteroaryl, c ycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted from 1 to 6 times by fluoro, -S(O) 2 H,
  • R is selected from aryl, heteroaryl, c ycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted from 1 to 6 times by fluoro, oxo,
  • R is selected from aryl, heteroaryl, c ycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, x y
  • R and R are each independently s elected from C 1-4 alkyl, and C 1-4 alkyl substituted with from 1 to 4 substituents independently selected from: fluoro, oxo, and–OH,
  • R is selected from aryl, heteroaryl, c ycloalkyl, heterocyloalkyl, C 1-6 alkyl, and C 1-6 alkyl substituted from 1 to 6 times by fluoro, x a
  • R is selected from aryl, heteroaryl, cycloalkyl, and heterocyloalkyl, aryl,

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PCT/IB2017/053511 2016-06-13 2017-06-13 Substituted pyridines as inhibitors of dnmt1 Ceased WO2017216727A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
PH1/2018/502633A PH12018502633B1 (en) 2016-06-13 2017-06-13 Substituted pyridines as inhibitors of dnmt1
CA3026211A CA3026211A1 (en) 2016-06-13 2017-06-13 Substituted pyridines as inhibitors of dnmt1
BR112018075992-9A BR112018075992B1 (pt) 2016-06-13 2017-06-13 Compostos de piridinas substituídas, composição e combinação farmacêutica compreendendo os ditos compostos, bem como usos terapêuticos dos compostos
AU2017283790A AU2017283790B2 (en) 2016-06-13 2017-06-13 Substituted pyridines as inhibitors of DNMT1
ES17733902T ES2993451T3 (en) 2016-06-13 2017-06-13 Substituted pyridines as inhibitors of dnmt1
MX2018015483A MX391600B (es) 2016-06-13 2017-06-13 Piridinas sustituidas como inhibidores de adn metiltransferasa-1 (dnmt1)
CR20180580A CR20180580A (es) 2016-06-13 2017-06-13 Piridinas sustituidas como inhibidores de dnmt1
KR1020197000766A KR20190017030A (ko) 2016-06-13 2017-06-13 Dnmt1의 억제제로서의 치환된 피리딘
EA201990023A EA038355B1 (ru) 2016-10-25 2017-06-13 Замещенные пиридины в качестве ингибиторов dnmt1
CN201780036908.XA CN109563043B (zh) 2016-06-13 2017-06-13 作为dnmt1的抑制剂的取代的吡啶
US16/309,121 US10975056B2 (en) 2016-06-13 2017-06-13 Substituted pyridines as inhibitors of DNMT1
JP2019517187A JP7051829B2 (ja) 2016-06-13 2017-06-13 Ｄｎｍｔ１の阻害剤としての置換ピリジン
SG11201809559UA SG11201809559UA (en) 2016-06-13 2017-06-13 Substituted pyridines as inhibitors of dnmt1
EP17733902.5A EP3468953B1 (en) 2016-06-13 2017-06-13 Substituted pyridines as inhibitors of dnmt1
IL263163A IL263163B (en) 2016-06-13 2018-11-21 Substituted pyridines as inhibitors of dnmt1
JOP/2018/0120A JOP20180120A1 (ar) 2016-06-13 2018-12-10 مشتقات بيريدين مستبدلة كمثبطات انتقائية لـ dnmt1
CONC2018/0013717A CO2018013717A2 (es) 2016-06-13 2018-12-18 Piridinas sustituidas como inhibidores de dnmt1

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662349227P 2016-06-13 2016-06-13
US62/349,227 2016-06-13
US201662393256P 2016-09-12 2016-09-12
US62/393,256 2016-09-12
US201662412343P 2016-10-25 2016-10-25
US62/412,343 2016-10-25

Publications (1)

Publication Number Publication Date
WO2017216727A1 true WO2017216727A1 (en) 2017-12-21

Family

ID=59239935

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2017/053511 Ceased WO2017216727A1 (en) 2016-06-13 2017-06-13 Substituted pyridines as inhibitors of dnmt1
PCT/IB2017/053509 Ceased WO2017216726A1 (en) 2016-06-13 2017-06-13 Substituted pyridines as inhibitors of dnmt1

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/053509 Ceased WO2017216726A1 (en) 2016-06-13 2017-06-13 Substituted pyridines as inhibitors of dnmt1

Country Status (20)

Country Link
US (1) US10975056B2 (enExample)
EP (1) EP3468953B1 (enExample)
JP (1) JP7051829B2 (enExample)
KR (1) KR20190017030A (enExample)
CN (1) CN109563043B (enExample)
AU (1) AU2017283790B2 (enExample)
CA (2) CA3026226A1 (enExample)
CL (1) CL2018003577A1 (enExample)
CO (1) CO2018013717A2 (enExample)
CR (1) CR20180580A (enExample)
DO (1) DOP2018000273A (enExample)
ES (1) ES2993451T3 (enExample)
IL (1) IL263163B (enExample)
JO (1) JOP20180120A1 (enExample)
MA (1) MA45244A (enExample)
MX (1) MX391600B (enExample)
PE (1) PE20190971A1 (enExample)
PH (1) PH12018502633B1 (enExample)
SG (1) SG11201809559UA (enExample)
WO (2) WO2017216727A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111662283A (zh) * 2019-03-07 2020-09-15 湖南化工研究院有限公司 咪唑并吡啶类化合物及其中间体、制备方法与应用
US10774054B2 (en) 2016-06-13 2020-09-15 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
US11225473B2 (en) 2019-01-15 2022-01-18 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
US11247986B2 (en) 2016-06-13 2022-02-15 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
WO2022185160A1 (en) * 2021-03-02 2022-09-09 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as dnmt1 inhibitors
US11524005B2 (en) 2019-02-19 2022-12-13 Gilead Sciences, Inc. Solid forms of FXR agonists
US11833150B2 (en) 2017-03-28 2023-12-05 Gilead Sciences, Inc. Methods of treating liver disease
CN119306700A (zh) * 2024-08-28 2025-01-14 山东大学 Dnmt1-hdac双靶点抑制剂及其制备方法和应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034786B1 (ru) 2015-08-13 2020-03-20 Мерк Шарп И Доум Корп. Циклические динуклеотидные соединения в качестве агонистов sting
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
TN2020000158A1 (en) 2016-10-04 2022-04-04 Merck Sharp & Dohme BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
EP3621624B1 (en) 2017-05-12 2023-08-30 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
US11285131B2 (en) 2017-08-04 2022-03-29 Merck Sharp & Dohme Corp. Benzo[b]thiophene STING agonists for cancer treatment
RU2020109328A (ru) 2017-08-04 2021-09-06 Мерк Шарп И Доум Корп. Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака
CN109651358B (zh) * 2017-10-11 2023-04-07 上海迪诺医药科技有限公司 4-氨基吡啶衍生物、其药物组合物、制备方法及应用
WO2019125974A1 (en) 2017-12-20 2019-06-27 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
WO2019195124A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Benzothiophenes and related compounds as sting agonists
WO2019195063A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
WO2022076563A1 (en) * 2020-10-07 2022-04-14 University Of Florida Research Foundation, Incorporated Macrocyclic compounds and methods of treatment
CN113502265B (zh) * 2021-05-25 2024-05-28 昭泰英基生物医药（香港）有限公司 将t细胞重编程为类nk细胞的诱导剂及其应用
CN113278021B (zh) * 2021-05-29 2022-09-23 天津全和诚科技有限责任公司 1,7-二氮杂螺[3.5]壬烷-7-甲酸叔丁酯及其草酸盐的制备方法
AU2022370354A1 (en) 2021-10-19 2024-05-30 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
CN114230459A (zh) * 2021-12-10 2022-03-25 武汉九州钰民医药科技有限公司 一种化合物的制备方法及分析检测方法
WO2023192629A1 (en) * 2022-04-01 2023-10-05 Herophilus, Inc. Induction of mecp2 expression by dna methyl transferase inhibitors
WO2024156288A1 (en) * 2023-01-29 2024-08-02 Shanghai Kygent Pharmaceutical Co., Ltd Dnmt1 inhibitors, pharmaceutical compositions, and therapeutic applications
WO2025006902A2 (en) * 2023-06-29 2025-01-02 Dana-Farber Cancer Institute, Inc. Synthesis and in vitro characterization of proteolysis targeting chimeras (protacs) for degradation of dna methyltransferase 1 (dnmt1)
WO2025085756A1 (en) * 2023-10-18 2025-04-24 University Of Florida Research Foundation, Incorporated Macrocyclic compounds and methods of treatment
WO2025190285A1 (en) * 2024-03-12 2025-09-18 Shanghai Kygent Pharmaceutical Co., Ltd Pyridine compounds, pharmaceutical compositions, and applications

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2030875A1 (en) 1990-11-26 1992-05-27 Alan R.P. Paterson Methods and probes for detecting nucleoside transporter and method for producing the probes
WO2006078752A2 (en) 2005-01-21 2006-07-27 Methylgene, Inc. Inhibitors of dna methyltransferase
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
KR20110027314A (ko) * 2009-09-10 2011-03-16 서울대학교산학협력단 ＴＮＦ-α 매개성 질환의 예방 및 치료용 조성물

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
ZA942125B (en) 1993-03-26 1994-11-10 Shell Res Ltd Herbicidal heterocyclic compounds.
CZ203798A3 (cs) 1995-12-29 1998-12-16 Smithkline Beecham Corporation Antagonista vitronektinového receptoru, farmaceutický přípravek s jeho obsahem, způsob a použití
AU1295597A (en) 1995-12-29 1997-07-28 Smithkline Beecham Corporation Vitronectin receptor antagonists
DE19947154A1 (de) * 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
EP1242366A1 (en) 1999-12-15 2002-09-25 Axys Pharmaceuticals, Inc. Salicylamides as serine protease and factor xa inhibitors
US6794506B2 (en) 2000-07-21 2004-09-21 Elan Pharmaceuticals, Inc. 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
US20030166554A1 (en) 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
DE10110754A1 (de) * 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10134481A1 (de) * 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
TW200406370A (en) 2002-06-28 2004-05-01 Syngenta Participations Ag 4-(3,3-Dihalo-allyloxy)phenoxy alkyl derivatives
TW200406152A (en) 2002-08-30 2004-05-01 Syngenta Participations Ag 4-(3,3-Dihalo-allyloxy) phenol derivatives having pesticidal properties
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
AR042344A1 (es) 2002-12-11 2005-06-15 Syngenta Participations Ag Derivados de 4-(3,3 - dihalo - aliloxi) fenol con propiedades pesticidas
SE0203712D0 (sv) 2002-12-13 2002-12-13 Astrazeneca Ab Novel compounds
CA2520323C (en) 2003-04-09 2013-07-09 Exelixis, Inc. Tie-2 modulators and methods of use
WO2004103954A1 (ja) 2003-05-20 2004-12-02 Ajinomoto Co., Inc. アミド誘導体
CN1856307A (zh) 2003-09-23 2006-11-01 默克公司 喹啉钾通道抑制剂
AU2011253934C1 (en) 2004-06-17 2013-08-22 Cytokinetics, Inc. Substituted urea derivatives for treating cardiac diseases
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
EP1655296A1 (en) 2004-10-25 2006-05-10 Graffinity Pharmaceuticals AG Thrombin inhibitors
GB0517740D0 (en) 2005-08-31 2005-10-12 Novartis Ag Organic compounds
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
EP2030971B1 (en) 2006-06-20 2011-10-12 Ishihara Sangyo Kaisha, Ltd. Pest control agent containing novel pyridyl-methanamine derivative or salt thereof
AU2008211729A1 (en) 2007-02-01 2008-08-07 Astrazeneca Ab 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
WO2009034433A2 (en) 2007-09-10 2009-03-19 Glenmark Pharmaceuticals, S.A. 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
ES2446932T3 (es) 2007-10-08 2014-03-10 Advinus Therapeutics Private Limited Derivados de acetamida como activadores de glucoquinasa, su procedimiento y aplicaciones en medicina
US8343966B2 (en) 2008-01-11 2013-01-01 Novartis Ag Organic compounds
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
WO2010007756A1 (ja) * 2008-07-14 2010-01-21 塩野義製薬株式会社 Ｔｔｋ阻害作用を有するピリジン誘導体
UY32055A (es) 2008-08-19 2010-03-26 Astrazeneca Ab Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20120238557A1 (en) 2009-11-13 2012-09-20 Shionogi & Co., Ltd. Aminothiazine or aminooxazine derivative having amino linker
KR101790255B1 (ko) 2009-12-23 2017-10-26 다케다 야쿠힌 고교 가부시키가이샤 Ｓｙｋ 억제제로서의 융합된 헤테로방향족 피롤리디논
CN102884062B (zh) 2009-12-23 2016-08-03 嘉世高制药公司 氨基嘧啶激酶抑制剂
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
WO2011103289A2 (en) 2010-02-17 2011-08-25 Jasco Pharmaceuticals, LLC Imidazole-2, 4-dione inhibitors of casein kinase 1
WO2011150156A2 (en) 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2012040636A2 (en) 2010-09-24 2012-03-29 The Broad Institute, Inc. Compounds and methods for treating diseases mediated by protease activated receptors
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
CA2824808A1 (en) 2011-01-17 2012-07-26 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
WO2012170931A2 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013019635A1 (en) 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013019621A1 (en) 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
EP2771012A4 (en) * 2011-10-24 2015-06-24 Glaxosmithkline Ip No 2 Ltd NEW CONNECTIONS
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
NZ706857A (en) 2012-09-28 2018-05-25 Ignyta Inc Azaquinazoline inhibitors of atypical protein kinase c
JP2017502968A (ja) 2014-01-21 2017-01-26 ウォックハート リミテッド ７−オキソ−１，６−ジアザビシクロ［３．２．１］オクタン誘導体及び抗菌剤としてのその使用
WO2015110999A1 (en) 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2030875A1 (en) 1990-11-26 1992-05-27 Alan R.P. Paterson Methods and probes for detecting nucleoside transporter and method for producing the probes
WO2006078752A2 (en) 2005-01-21 2006-07-27 Methylgene, Inc. Inhibitors of dna methyltransferase
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
KR20110027314A (ko) * 2009-09-10 2011-03-16 서울대학교산학협력단 ＴＮＦ-α 매개성 질환의 예방 및 치료용 조성물

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AKPAN I; BANZON V; IBANEZ V; VAITKUS K; DESIMONE J; LAVELLE D., DECITABINE INCREASES FETAL HEMOGLOBIN IN PAPIO ANUBIS BY INCREASING +:-GLOBIN GENE TRANSCRIPTION, vol. 38, 2010, pages 989 - 93
CHIN J; SINGH M; BANZON V; VAITKUS K; IBANEZ V; KOUZNETSOVA T ET AL., TRANSCRIPTIONAL ACTIVATION OF THE +:-GLOBIN GENE IN BABOONS TREATED WITH DECITABINE AND IN CULTURED ERYTHROID PROGENITOR CELLS INVOLVES DIFFERENT MECHANISMS, vol. 37, 2009, pages 1131 - 42
DOVER GJ; CHARACHE SH; BOYER SH; TALBOT J; SMITH KD., 5-AZACYTIDINE INCREASES FETAL HEMOGLOBIN PRODUCTION IN A PATIENT WITH SICKLE CELL DISEASE, vol. 134, 1983, pages 475 - 88
LEY TJ; DESIMONE J; NOGUCHI CT; TURNER PH; SCHECHTER AN; HELLER P ET AL., AZACYTIDINE INCREASES +:-GLOBIN SYNTHESIS AND REDUCES THE PROPORTION OF DENSE CELLS IN PATIENTS WITH SICKLE CELL ANEMIA, vol. 62, 1983, pages 370 - 80
LOWREY CH; NIENHUIS AW., BRIEF REPORT: TREATMENT WITH AZACITIDINE OF PATIENTS WITH END-STAGE +:- THALASSEMIA, vol. 329, 1993, pages 845 - 8
MABAERA R; RICHARDSON CA; JOHNSON K; HSU M; FIERING S; LOWREY CH, DEVELOPMENTAL- AND DIFFERENTIATION-SPECIFIC PATTERNS OF HUMAN +:- AND +:-GLOBIN PROMOTER DNA METHYLATION, vol. 110, 2007, pages 1343 - 52
POP R; SHEARSTONE JR; SHEN Q; LIU Y; HALLSTROM K; KOULNIS M ET AL., A KEY COMMITMENT STEP IN ERYTHROPOIESIS IS SYNCHRONIZED WITH THE CELL CYCLE CLOCK THROUGH MUTUAL INHIBITION BETWEEN PU.1 AND S-PHASE PROGRESSION., 2010, pages 8
SAUNTHARARAJAH Y; HILLERY CA; LAVELLE D; MOLOKIE R; DORN L; BRESSLER L ET AL., EFFECTS OF 5-AZA-2GÇ-DEOXYCYTIDINE ON FETAL HEMOGLOBIN LEVELS, RED CELL ADHESION, AND HEMATOPOIETIC DIFFERENTIATION IN PATIENTS WITH SICKLE CELL DISEASE, vol. 102, 2003, pages 3865 - 70
SHEARSTONE JR; POP R; BOCK C; BOYLE P; MEISSNER A; SOCOLOVSKY M., GLOBAL DNA DEMETHYLATION DURING MOUSE ERYTHROPOIESIS IN VIVO, vol. 334, 2011, pages 799 - 802
TING ET AL., GENES DEV, vol. 20, 2006, pages 3215 - 3231
ZHOU ET AL., ONCOL. LETT, vol. 5, 2014, pages 2130 - 2134

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11739065B2 (en) 2016-06-13 2023-08-29 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
US10774054B2 (en) 2016-06-13 2020-09-15 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
US10981881B2 (en) 2016-06-13 2021-04-20 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
US12358903B2 (en) 2016-06-13 2025-07-15 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
US11247986B2 (en) 2016-06-13 2022-02-15 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
US11833150B2 (en) 2017-03-28 2023-12-05 Gilead Sciences, Inc. Methods of treating liver disease
US11225473B2 (en) 2019-01-15 2022-01-18 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
US11524005B2 (en) 2019-02-19 2022-12-13 Gilead Sciences, Inc. Solid forms of FXR agonists
US12102625B2 (en) 2019-02-19 2024-10-01 Gilead Sciences, Inc. Solid forms of FXR agonists
CN111662283A (zh) * 2019-03-07 2020-09-15 湖南化工研究院有限公司 咪唑并吡啶类化合物及其中间体、制备方法与应用
US11771711B2 (en) 2021-03-02 2023-10-03 GlaxoSmith Kline Intellectual Property Development Limited Substituted pyridines as DNMT1 inhibitors
WO2022185160A1 (en) * 2021-03-02 2022-09-09 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as dnmt1 inhibitors
AU2022230795B2 (en) * 2021-03-02 2025-02-13 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as dnmt1 inhibitors
US12285436B2 (en) 2021-03-02 2025-04-29 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as DNMT1 inhibitors
CN119306700A (zh) * 2024-08-28 2025-01-14 山东大学 Dnmt1-hdac双靶点抑制剂及其制备方法和应用

Also Published As

Publication number Publication date
AU2017283790A1 (en) 2018-11-22
ES2993451T3 (en) 2024-12-30
BR112018075992A2 (pt) 2019-04-02
AU2017283790B2 (en) 2019-08-29
JP2019517596A (ja) 2019-06-24
US10975056B2 (en) 2021-04-13
CA3026211A1 (en) 2017-12-21
PE20190971A1 (es) 2019-07-09
KR20190017030A (ko) 2019-02-19
CN109563043A (zh) 2019-04-02
CA3026226A1 (en) 2017-12-21
JOP20180120A1 (ar) 2019-01-30
SG11201809559UA (en) 2018-12-28
IL263163B (en) 2021-10-31
PH12018502633B1 (en) 2023-02-01
PH12018502633A1 (en) 2019-09-30
MA45244A (fr) 2019-04-17
EP3468953B1 (en) 2024-05-22
WO2017216726A1 (en) 2017-12-21
MX391600B (es) 2025-03-21
CR20180580A (es) 2019-07-02
EP3468953C0 (en) 2024-05-22
DOP2018000273A (es) 2019-03-31
CN109563043B (zh) 2022-05-31
IL263163A (en) 2018-12-31
US20190194166A1 (en) 2019-06-27
CO2018013717A2 (es) 2019-01-18
MX2018015483A (es) 2019-03-18
EP3468953A1 (en) 2019-04-17
CL2018003577A1 (es) 2019-04-05
JP7051829B2 (ja) 2022-04-11

Similar Documents

Publication Publication Date Title
AU2017283790B2 (en) Substituted pyridines as inhibitors of DNMT1
JP6373973B2 (ja) Ｚｅｓｔｅホモログ２エンハンサー阻害剤
JP5743897B2 (ja) 化合物
JP6430390B2 (ja) Ｔ７９０ｍを含むｅｇｆｒ変異体の阻害剤としてのアミノピリミジン化合物
KR101862493B1 (ko) Fgfr4 억제제로서의 고리-융합된 비시클릭 피리딜 유도체
EP3052494B1 (en) Azaindazole compounds as inhibitors of t790m containing egfr mutants
KR20240128852A (ko) 암 치료를 위한 고리형 2-아미노-3-시아노 티오펜 및 유도체
CN107922409A (zh) 作为parp抑制剂的杂芳基衍生物
WO2019049061A1 (en) 5- (1H-BENZO [D] IMIDAZO-2-YL) -PYRIDIN-2-AMINE AND 5- (3H-IMIDAZO [4,5-B] PYRIDIN-6-YL) -PYRIDIN-2- DERIVATIVES AMINE AS HISTONE ACETYLTRANSFERASE INHIBITORS OF C-MYC AND P300 / CBP FOR THE TREATMENT OF CANCER
MX2012011045A (es) Novedosos derivados de indolina sustituidos.
AU2013371541A1 (en) Enhancer of Zeste Homolog 2 inhibitors
AU2014276417A1 (en) Enhancer of Zeste Homolog 2 inhibitors
WO2015056180A1 (en) Indoline derivatives as inhibitors of perk
BR112018075992B1 (pt) Compostos de piridinas substituídas, composição e combinação farmacêutica compreendendo os ditos compostos, bem como usos terapêuticos dos compostos
NZ747748A (en) Substituted pyridines as inhibitors of dnmt1

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2017283790

Country of ref document: AU

Date of ref document: 20170613

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17733902

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3026211

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019517187

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: NC2018/0013717

Country of ref document: CO

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018075992

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: DZP2018000661

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 20197000766

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017733902

Country of ref document: EP

Effective date: 20190114

WWP Wipo information: published in national office

Ref document number: NC2018/0013717

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 112018075992

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20181213

WWG Wipo information: grant in national office

Ref document number: NC2018/0013717

Country of ref document: CO